Tempest Therapeutics Inc. Enters into Exclusive License Agreement with the University of California for Novel Cancer Target
September 13, 2021 at 08:00 am EDT
Tempest Therapeutics Inc. announced that it has entered into an exclusive license with the University of California at Berkeley for intellectual property covering a drug target that was discovered in the laboratory of Russell Vance, Ph.D., professor of molecular and cell biology at U.C. Berkeley and a Howard Hughes Medical Institute investigator.